Ipsos Launches Immuno-Oncology Mental Mapping Study

Ipsos has unveiled a new syndicated tool called the Immuno-Oncology (I-O) Mental Mapping Study, available first in China, with other countries in development.

The study uses the firm's EquityVision research framework, providing an in-depth perceptual view of the classes, products and companies active within the I-O space. Specifically, it aims to uncover oncologists' awareness of I-O products, their current and future usage and their perceptions of manufacturers, access and affordability. In addition, the EquityVision mental mapping component will uncover how oncologists and other cancer-treating specialists perceive different brands. Subscribers to the study will be helped to understand both the differentiation of their product and its likely future uptake within the competitive landscape.

The study is currently running in three Tier 1 and eight Tier 2 cities in China and will be rolled out to other countries in 2019. Pieter De Richter, Head of Ipsos' Syndicated Real World Evidence Portfolio in APAC and MENA, says: 'How oncologists perceive and choose between these highly similar I-O brands is difficult to ascertain using traditional research methods. The new study will help us to understand what is truly salient to physicians and how to put a brand story into its competitive context. Furthermore, the study covers awareness and predicted usage of other emerging I-O therapies that are on the horizon in China, such as the CAR-T class'.

Web site: www.ipsos.com .